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Abstract
Mitochondrial dysfunction within the pulmonary vessels has been shown to contribute to the pathology of idiopathic pulmonary
arterial hypertension (IPAH). We investigated the hypothesis of whether impaired exercise capacity observed in IPAH patients is in
part due to primary mitochondrial oxidative phosphorylation (OXPHOS) dysfunction in skeletal muscle. This could lead to
potentially new avenues of treatment beyond targeting the pulmonary vessels. Nine clinically stable participants with IPAH under-
went cardiopulmonary exercise testing, in vivo and in vitro assessment of mitochondrial function by 31P-magnetic resonance
spectroscopy (31P-MRS) and laboratory muscle biopsy analysis. 31P-MRS showed abnormal skeletal muscle bioenergetics with
prolonged recovery times of phosphocreatine and abnormal muscle pH handling. Histochemistry and quadruple immunofluores-
cence performed on muscle biopsies showed normal function and subunit protein abundance of the complexes within the
OXPHOS system. Our findings suggest that there is no primary mitochondrial OXPHOS dysfunction but raises the possibility
of impaired oxygen delivery to the mitochondria affecting skeletal muscle bioenergetics during exercise.
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Introduction
Idiopathic pulmonary arterial hypertension (IPAH) remains
a progressive disease leading to premature death despite the
availability of effective targeted therapies.1 Patients report
not only breathlessness, but fatigue as one of the predom-
inant symptoms.2 Beyond the obstruction observed in the
pulmonary vessels, a number of other organs are involved in
IPAH. These include the presence of insulin resistance, skel-
etal muscle dysfunction, bone-marrow derived mononuclear
cells, and iron deficiency.3 In terms of skeletal muscle
changes, a shift in muscle fiber types—from type I to type
II—with a concomitant change in the metabolic profile from
oxidative to glycolytic, imbalance in the muscle protein
breakdown, and synthesis pathways have been recorded in
these patients.4 Impaired mitochondrial function has been
shown to contribute to the pathology of the disease within
the pulmonary vessels but whether there is mitochondrial
dysfunction in the skeletal muscle is unclear.5 In particular,
the question arises as to whether impairment of the oxida-
tive phosphorylation (OXPHOS) process, the final pathway
to energy generation within the mitochondria, is
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contributing to exercise intolerance in IPAH. Therefore, we
tested the hypothesis that in IPAH, there is skeletal muscle
mitochondrial OXPHOS dysfunction affecting exercise cap-
acity. We undertook a pilot study using both in vitro and
in vivo methods.
Methods
Nine participants were recruited from the National
Pulmonary Hypertension Service (Newcastle) and were
deemed clinically stable on targeted IPAH-specific therapy
for at least three months. All nine participants underwent
symptom-limited cardiopulmonary exercise testing with six
patients having simultaneous non-invasive hemodynamic
measurements, vastus lateralis muscle biopsy, 6-min walk
distance (6MWD), and completion of two questionnaires:
EmPHasis-10 and Fatigue Severity Scale (FSS). Six partici-
pants underwent 31P magnetic resonance spectroscopy
(31P-MRS) scans. Three were unable to undergo 31P-MRS
due to prostacyclin pumps proving to be a contraindication.
Muscle biopsies underwent mitochondrial OXPHOS assess-
ment by histochemistry and quadruple immunofluorescence,
as previously reported.6,7 31P-MRS scan was performed
using 3T Achieva Scanner (Philips, NL) with a 14-cm diam-
eter phosphorous surface coil for transmission /reception for
signal and the in-built body coil for anatomical imaging, as
previously reported, to obtain PCr and ADP half-times.8
Approval for the study was obtained from the regional
ethics committee.
Results
Baseline and exercise characteristics of individual partici-
pants are summarized in the table in Fig. 1. Five IPAH
patients reported to be suffering fatigue scores> 4, with
three patients reporting severe symptoms (FSS> 5).
Representative examples of the evolution in phospho-
creatine (PCr) concentration and intramuscular pH changes
during exercises as assessed by 31P-MRS are shown in
Fig. 2a and b. The results of the IPAH patients in compari-
son to referenced historical control values8 are shown in
Fig. 2c. The six participants who underwent 31P-MRS
scans, exhibited higher phosphocreatine recovery time kin-
etics (PCr t1/2) (40.0 8.8 versus 27.2 7.1 s, P¼ 0.013) and
achieved lower minimum pH values (6.85 0.10 versus
7.00 0.02, P¼ 0.001), but had normal ADP recovery kin-
etics (25.5 7.1 versus 20.9 5.1 s, P¼ 0.228), rest pH
(7.03 0.02 versus 7.03 0.04, P¼ 0.573), and end pH
(7.02 0.04 versus 7.02 0.02, P¼ 0.573). IPAH patients
demonstrated evidence of an increase in pH recovery times
compared to controls (197 s, range¼ 130–240 s versus 58 s,
range¼ 0–160 s).
The COX/SDH histochemical assay, which allows detec-
tion of enzymatic activity of succinate dehydrogenase
(SDH) and cytochrome c oxidase (COX), did not reveal
any respiratory-deficient myofibres in patients. This was
also supported by modified Gomori trichrome staining
that demonstrated absence of any ragged-red fibres, other-
wise commonly found in primary mitochondrial myopa-
thies. In order to corroborate our findings, quadruple
immunofluorescence to assess abundance of selected protein
subunits of complex I and IV of the mitochondrial respira-
tory chain was subsequently undertaken. We compared the
results to skeletal muscle biopsy samples of two healthy
normal controls and a patient with genetically-defined mito-
chondrial DNA disease, as positive control. Representative
results are shown in the panels in Figure 1a–d. These
demonstrated normal levels (within 3 standard deviations
[SD]) of complex I and IV in all nine muscle samples
obtained from IPAH patients comparative to normal
healthy controls.
Discussion
This pilot study assessed skeletal muscle mitochondrial
function using in vivo and in vitro methods in idiopathic
pulmonary arterial hypertension. First, we have shown evi-
dence of abnormal skeletal muscle bioenergetics by
31P-MRS during and after exercise that could either be
explained by mitochondrial OXHOS dysfunction or
impaired oxygen delivery to the mitochondria. We went
on to show in the same patients, there were normal levels
of mitochondrial respiratory chain protein abundance as
well as preserved enzymatic activity in skeletal muscle, irre-
spective of disease burden. Therefore, these findings sug-
gest oxygen delivery rather than utilization to the skeletal
muscle is affecting muscle function and impairing exercise
capacity.
COX/SDH histochemistry is the gold standard method to
interrogate COX and SDH activities in individual muscle
fibers. The qualitative analysis of sequentially labelled
muscle sections obtained from IPAH patients revealed
that both complex II and IV activities were normal. This
was confirmed by quadruple immunofluorescence, a new
state-of-the-art methodology that is a very sensitive and
accurately quantifies abundance of complex I and IV sub-
units of the OXPHOS system in each individual muscle
myofiber, with correction for mitochondrial mass.7 We
observed normal levels of complex I and IV in all nine
IPAH patients. We studied IPAH patients who were clinic-
ally stable and free from significant co-morbidities which
could be considered a drawback. Nevertheless, we should
note that three of the patients were on intravenous therapy
(Iloprost), including one patient who underwent lung
transplantation within one year of the muscle biopsy.
Therefore, our study supports the assertion there is no skel-
etal muscle mitochondrial OXPHOS dysfunction in IPAH.
The abnormal skeletal muscle bioenergetics observed in
31P-MRS are likely due to impaired oxygen delivery to the
muscle mitochondria. The reduced oxygen delivery could be
due to central and peripheral factors as shown in previous
studies including reduced cardiac output, decreased muscle
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Fig. 1. Table: Baseline clinical characteristics of the nine IPAH patients including age, gender, treatment, quality of life scores, peak oxygen
consumption (VO2), peak cardiac index (CI), maximum peripheral oxygen extraction (arterial-venous O2 difference), and the oxygen con-
sumption – work rate relationship (VO2/WR). (a–d) The mitochondrial respiratory chain profile (levels of complex I, complex IV, and porin)
in selected patients: (a) Healthy control (male, 49 years, n¼ 238). (b)IPAH (Patient 4, n¼ 317). (c) IPAH (Patient 1, n¼ 166). (d) Patient with
genetically defined mitochondrial DNA disease (positive control; male, 60 years, n¼ 188). n is the number of fibers analyzed in each muscle
section. Each dot represents the measurement from an individual muscle fiber, with color according to the mitochondrial mass (very low: blue,
low: light blue, normal: light orange, high: orange, and very high: red). The thin black lines indicate the SD limits for classification of the fibers. Bold
dashed lines indicate the mean abundance level of complex I (NDUFB8) and complex IV (COX-I) in normal fibers.
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capillarization, diminished angiogenesis, and abnormal per-
ipheral microcirculation.9 Indirect evidence in IPAH exists
of impaired oxygen delivery to utilization mismatch at the
onset of exercise affecting oxygen uptake kinetics (VO2).
10
As a result, energy (ATP) is generated in the muscle through
oxygen-independent pathways leading to accumulation of
by-products that may cause muscle fatigue. Currently we
are unclear about the dominant mechanism impairing
both oxygen delivery and extraction during exercise in
IPAH. Exercise training has been shown to be beneficial
in improving cardiac output, muscle capillarization, exercise
endurance capacity, and muscle strength in IPAH.11,12 Our
findings support the potential benefits of structured exercise
training programs to improving central and peripheral fac-
tors in oxygen delivery to the muscle mitochondria.
Furthermore, there are no licensed pharmacological thera-
pies available in improving peripheral factors affecting
oxygen transport pathway and, currently, support the role
of exercise in IPAH. However, there is evidence that dietary
nitrate has an impact on skeletal muscle vascular and meta-
bolic control during exercise with efficacy in the pre-clinical
and clinical chronic heart failure.13 Therefore, further
research is much needed to determine if there is a role for
pharmacology to improve peripheral skeletal muscle func-
tion during exercise in IPAH.
In conclusion, impaired exercise capacity and skeletal
muscle bioenergetics is not explained by mitochondrial
OXPHOS dysfunction in IPAH, suggesting oxygen delivery
rather than utilization as the main factor contributing to
exercise intolerance. Improving exercise capacity in IPAH
requires addressing the primary impediments including car-
diac output, muscle capillarization, and peripheral microcir-
culation for adequate oxygen delivery to the skeletal muscle.
Further research into both pharmacology and exercise pre-
scriptions to improve peripheral factors that affect the
oxygen transport pathway in IPAH is much needed.
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Fig. 2. (a, b) Tracing of the intramuscular PCr concentration decay (a) and change in pH (b) during rest, exercise, and recovery are shown.
Start of exercise was at 80 s and recovery commenced at 260 s. (c) Table demonstrating the comparisons between healthy control data8 and
IPAH patients. Values are mean SD. Non-parametric independent data analyzed by Mann–Whitney U test. P value< 0.05 was considered
significant.
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